It is known that the two types of FK506-binding proteins FKBP12 and FKBP12.6 are tightly associated with the skeletal (RyR1) and cardiac ryanodine receptors (RyR2), respectively, and their interactions are important for channel functions of the RyR. In the case of cardiac muscle, three amino acid residues (Gln-31, Asn-32, and Phe-59) of FKBP12.6 could be essential for the selective binding to RyR2 (Xin, H. B., Rogers, K., Qi, Y., Kanematsu, T., and Fleischer, S. (1999) J. Biol. Chem. 274, 15315-15319). In this study to identify amino acid residues of FKBP12 that are important for the selective binding to RyR1, we mutated 9 amino acid residues of FKBP12 that differ from the counterparts of FKBP12.6 (Q3E, R18A, E31Q, D32N, M49R, R57A, W59F, H94A, and K105A), and we examined binding properties of these mutants to RyR1 by in vitro binding assay by using glutathione S-transferase-fused proteins of the mutants and Triton X-100-solubilized, FKBP12-depleted rabbit skeletal sarcoplasmic reticulum vesicles. Among the nine mutants tested, only Q3E and R18A lost their selective binding ability to RyR1. Furthermore, co-immunoprecipitation of RyR1 with 33 various mutants for the 9 positions produced by introducing different size, charge, and hydrophobicity revealed that an integration of the hydrogen bonds by the irreplaceable Gln-3 and the hydrophobic interactions by the residues Arg-18 and Met-49 could be a possible mechanism for the binding of FKBP12 to RyR1. Therefore, these results suggest that the N-terminal regions of FKBP12 (Gln-3 and Arg-18) and Met-49 are essential and unique for binding of FKBP12 to RyR1 in skeletal muscle.
The ryanodine receptor (RyR) 1 in striated muscles is a high conductance Ca 2ϩ release channel (CRC) located in the terminal cisternae of sarcoplasmic reticulum (SR) (1) (2) (3) (4) (5) . In skeletal muscle, activation of the dihydropyridine receptor/voltage sensor by membrane depolarization induces conformational changes of RyR1 and opening of the CRC leading to release of Ca 2ϩ from the SR and muscle contraction. In cardiac muscle, depolarization-induced Ca 2ϩ influx through the dihydropyridine receptor/L-type Ca 2ϩ channel induces Ca 2ϩ release from the SR via RyR2/CRC, Ca 2ϩ -induced Ca 2ϩ release, and muscle contraction. A third isoform, RyR3, is more ubiquitously expressed with much lower levels compared with RyR1 and RyR2 and may exert some functional role in Jurkat T cells, parotid acinar cells, central nervous systems, and neonatal and adult skeletal muscle (6 -9) .
FKBP12 is an FK506-binding protein that has functions of immunophilin as well as being a peptidyl-prolyl cis-trans isomerase (PPIase) (10) . It participates in various cellular processes such as neurotransmitter release, neural nitric oxide production, and signal transduction via the type 1 receptor for transforming growth factor-␤ (11) . FKBP12 is also tightly associated with RyR1 at a molar ratio of (FKBP12) 4 /(RyR1 monomer) 4 (12, 13) . Single particle reconstruction maps have shown that FKBP12 is located at the edge of its clamp-shaped cytoplasmic assembly of RyR1 (14, 15) . In cardiac muscle, FKBP12.6 was found to be selectively associated with RyR2 at a molar ratio of (FKBP12.6) 4 /(RyR2 monomer) 4 (12, 13, 16 -20) . FKBP12.6 shares structural and functional similarities with FKBP12 such as high amino acid sequence homology (e.g. 85% in human) (18, 21) , having PPIase activity that is inhibited by immunosuppressive drugs such as FK506 and rapamycin (22) (23) (24) , and promoting full conductance state gating of CRC (17, 25) .
RyR1 in skeletal muscle from animals having heart failure under a chronic hyperadrenergic state was cAMP-dependent protein kinase-hyperphosphorylated and depleted of FKBP12 and exhibited increased channel activities (26) . In lipid bilayers, RyR1 is profoundly activated by the depletion of FKBP12 by using FK506 or rapamycin, as evidenced by a greater mean open probability due to longer mean open time and dominant sub-conductance states (13, (27) (28) (29) (30) . These drugs also alter the sensitivity of RyR1 to effectors and affect full gating properties (13, 16, 25, 27, 28) . FKBP12.6-depleted RyR2 shows an increased gating frequency of the channel manifested by reduced open and closed dwell times (19, 31, 32) . In the case of FKBP12. 6 , it has been reported that three amino acid residues, Gln-31, Asn-32, and Phe-59 of FKBP12. 6 Preparation of SR Vesicles from Rabbit Skeletal Muscle-A heavy fraction of SR vesicles was prepared from rabbit back and leg fast twitch muscle using a modification of a procedure described elsewhere (34) . Briefly, about 150 g of muscle was homogenized in a Waring blender with 4 volumes of a 2.5 mM NaOH solution for 20 s six times at intervals of 3 min. During the homogenization, the pH was adjusted to 6.8. The suspension was centrifuged at 10,000 ϫ g for 3 min. The supernatant was filtered through eight layers of cheesecloth and then through Whatman No. 4 filter papers. After readjusting the pH to 6.8, the filtrate was centrifuged again at 17,000 ϫ g for 30 min. The pellets were suspended in a final solution containing 0.15 M KCl, 20 mM MOPS, pH 7.4, and 0.3 M sucrose in the presence of the protease inhibitors (1 M pepstatin, 1 M leupeptin, 100 M phenylmethylsulfonyl fluoride (PMSF), and 1 M trypsin inhibitor). The suspension was centrifuged again at 17,000 ϫ g for 30 min. The pellets were resuspended in the same final solution, and the final protein concentration was determined by the Bradford method by using bovine serum albumin as the standard. The obtained SR vesicles were quickly frozen in liquid N 2 and then stored at Ϫ70°C until use.
Preparation and Solubilization of FKBP12-depleted SR Vesicles-FKBP12-depleted SR vesicles (ϪFSR) were prepared using a modification of a procedure described previously (30) . The SR vesicles (2 mg/ml) were incubated with 20 M rapamycin in a solution containing 0.15 M KCl, 20 mM MOPS, pH 7.4, and 0.3 M sucrose in the presence of the protease inhibitors (1 M pepstatin, 1 M leupeptin, 100 M PMSF, and 1 M trypsin inhibitor) at 37°C for 15 min. Solutions for control incubation without rapamycin and for incubation with rapamycin contained Ͻ1% ethanol that was used as the solvent for rapamycin. Following the incubation, the suspension was centrifuged again at 17,000 ϫ g for 30 min. The pellets were resuspended in the same solution and then subjected to solubilization in a lysis buffer containing 1% Triton X-100, 10 mM Tris-HCl, pH 7.4, 1 mM Na 3 VO 4 , 10% glycerol, 150 mM NaCl, 5 mM EDTA, and protease inhibitors (1 M pepstatin, 1 M leupeptin, 1 mM PMSF, and 1 M trypsin inhibitor) for 3 h at 4°C. The solubilized FSR (Sol-FSR) was centrifuged at 150,000 ϫ g for 20 min. The supernatant was collected and diluted 1:10 with a dilution buffer containing 10 mM Tris-HCl, pH 7.4, 1 mM Na 3 VO 4 , 10% glycerol, 150 mM NaCl, and 5 mM EDTA with protease inhibitors (1 M pepstatin, 1 M leupeptin, 1 mM PMSF and 1 M trypsin inhibitor) and then subjected to in vitro binding assay or co-immunoprecipitation with various GST-mFKBPs.
cDNA Cloning of FKBP12.6 from Rabbit Heart-Total RNA of rabbit heart was isolated using an RNeasy mini kit (Qiagen, Valencia, CA). cDNA was synthesized by random hexamer and oligo(dT) primer using Omniscript reverse transcriptase (Qiagen, Valencia, CA). To amplify the complete cDNA sequence of FKBP12.6 (324 bp), two oligonucleotide primers were designed based on the nucleotide sequence of a human FKBP12.6 (GenBank TM accession number L37086). The forward primer was 5Ј-GAGGCGGGGCCTGTG-3Ј, corresponding to nucleotides 44 -58, and the reverse primer was 5Ј-CCATCTCCAGCCACCTTG-3Ј, corresponding to nucleotides 409 -426. With these primers, PCR was performed with 30 cycles of 94°C for 30 s, 57°C for 30 s, and 72°C for 90 s with a GeneAmp 2700 thermal cycler (Applied Biosystems, Foster City, CA). The product was cloned into pCR2.1-TOPO vector (Invitrogen) and sequenced on both strands by automated DNA sequencing using the ABI 3700 sequencer (PerkinElmer Life Sciences). The complete cDNA sequence of FKBP12.6 from rabbit heart is 5Ј-atgggcgtggagatcgagaccatctcccccggagacgggaggacgtttcccaagaagggccaaacgtgtgtggtgcactacacaggaatgctccaaaatgggaagaaatttgattcatccagagacagaaacaaacctttcaagttccgaattggcaaacaggaagtcatcaaaggtttcgaagaaggtgcagcccagatgagcttggggcagagggcgaagctgacctgcacccctgatgtggcatacggagccacgggccaccccggtgtcatccctcccaatgccaccctcatctttggcgtggagctgctcaacttagagtga-3Ј. The deduced amino acid sequence is 0 MGVEIETISPGDGRTFPKKGQTCV-VHYTGMLQNGKKFDSSRDRNKPFKFRIGKQEVIKGFEEGAAQMS-LGQRAKLTCTPDVAYGATGHPG VIPPNATLIFGVELLNLE 107 .
Preparation of Mutated or Deleted FKBP12s and FKBP12.6s-The
cDNA clone of human FKBP12 in pGEM-3Zf(ϩ) (Promega, Madison, WI) was a generous gift from Dr. S. L. Schreiber. Based on the fact that the human FKBP12 clone has the same amino acid sequence with that from Oryctolagus cuniculus (rabbit) skeletal muscle (11) (GenBank TM accession number M89928), the human FKBP12 clone was used instead of a rabbit skeletal FKBP12 clone in this study. The preparation of the FKBP12 mutants (mFKBP12) was carried out using the site-directed mutagenesis system (QuickChange site-directed mutagenesis kit, Stratagene, La Jolla, CA). Briefly, by using the FKBP12 clone as a DNA template, the mutants were synthesized by PCR in the presence of a pair of complementary synthetic oligonucleotide primers containing the desired mutation by using Pfu DNA polymerase that replicates both plasmid strands with high fidelity and without displacing the mutant oligonucleotide primers. Following temperature cycling of PCR, the parental DNA template was digested by DpnI endonuclease that is specific for cleaving methylated and semi-methylated DNA, and the nicked vector DNA incorporating the desired mutations was then transformed into XL1-Blue supercompetent cells. To make the deleted mutant of FKBP12 (Del-FKBP12) that lacks the N-terminal 18 residues, synthetic oligonucleotide forward primer containing the nucleotide sequence corresponding to amino acids 19 -21 with the EcoRI site at the 5Ј end and the reverse primer containing complementary nucleotide sequence corresponding to amino acids 105-107 with SalI site at 5Ј end were used for the amplification of the deleted cDNA fragment of The PCR fragment was also subcloned into the pGEM-3Zf(ϩ) vector at EcoRI and HindIII sites. The sequence of all mutants was confirmed by sequencing using an Applied Biosystems Prism 377 automatic sequencer (Applied Biosystems, Foster City, CA) with a dye terminator Cycle Sequencing Ready Reaction kit (PerkinElmer Life Sciences).
The same procedure described above was used to make mutated FKBP12.6s (mFKBP12.6s) except for using rabbit skeletal FKBP12.6 clone as a template. First, the FKBP12.6 clone from pCR2.1-TOPO was subcloned into the pGEM-3Zf(ϩ) vector at EcoRI and HindIII sites and subjected to site-directed mutagenesis. For the deletion mutant of FKBP12.6 (Del-FKBP12.6), the same strategy as was used for the FKBP12 deletion was applied.
Preparation and Purification of GST-mFKBPs-To make GST-fused FKBPs (GST-FKBPs), 35 mutated FKBP12/12.6 clones, 2 deletion clones, and 2 wild type clones (FKBP12 and FKBP12.6) were subcloned into the pGEX-4T-1 or pGEX-4T-3 (Amersham Biosciences) between the EcoRI and SalI sites. Production of recombinant GST-FKBPs was induced in log phase BL21 Escherichia coli containing the desired plasmid by the addition of 0.1 mM isopropyl-␤-D-thiogalactopyranoside for 3 h at 37°C, and bacterial cell lysates were prepared by sonication. After centrifugation of the lysates at 1400 ϫ g, the supernatants were incubated with glutathione-Sepharose 4B affinity beads for 3 h at 4°C. After washing the beads five times with phosphate-buffered saline (PBS) with the protease inhibitors (1 M pepstatin, 1 M leupeptin, 100 M PMSF, and 1 M trypsin inhibitor), the bound proteins were subjected to further in vitro binding assay or elution by boiling in SDS sample buffer (35) . The eluted proteins were subjected to SDS-PAGE and Coomassie Blue stain. To remove the GST moiety to control for possible differences in binding affinity caused by GST, GST-fused wild type FKBP12 (wtFKBP12) and Q3A were purified by glutathioneSepharose 4B affinity beads and subjected to thrombin digestion for 16 h at 22°C (0.2 NIH unit of thrombin/100 g of GST-fused protein), and the thrombin was removed from the supernatant by passing it over a HiTrap FF thrombin column. The eluted GST-free wtFKBP12 and Q3A (20 g of GST-free FKBPs) were then used as indicated below for co-immunoprecipitation studies.
In Vitro Binding Assay of GST-FKBPs with Sol-FSR-In vitro binding assays were performed using a modification of a procedure described previously (36) . Affinity beads were prepared by the immobilizing 100 g of GST-FKBPs on glutathione-Sepharose 4B. The affinity beads were then incubated with 150 g of the Sol-FSR for 4 h at 4°C. After the incubation, the protein-bead complexes were washed five times with a buffer containing 20 mM Tris-HCl, pH 7.4, and 0.15 M NaCl, and protease inhibitors (1 M pepstatin, 1 M leupeptin, 100 M PMSF, and 1 M trypsin inhibitor). The bound proteins were eluted by boiling in the SDS sample buffer. The eluates were subjected to SDS-PAGE for immunoblot with the anti-RyR1 and anti-FKBP12 antibodies.
Co-immunoprecipitation-For immunoprecipitation studies, the supernatants (30 g) of the bacterial cell lysate containing each GSTmFKBP12 or GST-free FKBP12s (20 g) were mixed and incubated with 80 g of the Sol-FSR for 8 h at 4°C. The mixed samples were incubated for 4 h at 4°C with the monoclonal anti-RyR1 antibody, followed by incubation with protein G-Sepharose affinity beads for 4 h at 4°C. The protein-bead complexes were washed repeatedly with PBS with the protease inhibitors (1 M pepstatin, 1 M leupeptin, 100 M PMSF, and 1 M trypsin inhibitor) to remove nonspecifically bound proteins. The bound proteins were eluted by boiling in the SDS sample buffer and subjected to SDS-PAGE for immunoblot with the anti-RyR1 and anti-FKBP12 antibodies.
Immunoblot-For immunoblot, the denatured samples in the SDS sample buffer were subjected to 8, 10 (for RyR1), 12, or 15% (for GST-FKBPs) SDS-PAGE. Electrophoresis was performed at 60 V for RyR1s and 100 V for GST-FKBPs. The proteins on the gel were transferred onto nitrocellulose membrane at 100 V for 1 h. The membranes were incubated with either anti-RyR1 (1:5000) or anti-FKBP12 (1:5000) antibody for 2 h at 4°C, washed with PBS with 0.1% Tween 20 (PBST), and then incubated with horseradish peroxidase-conjugated goat antimouse (1:20,000) or donkey anti-goat IgG antibody (1:20,000), respectively, for 45 min at room temperature. The membranes were washed three times with PBST and developed by using SuperSignal ultrachemiluminescent substrate (Pierce). CD Measurements-CD spectra of mFKBP12s were measured on a Jasco J-715 CD spectropolarimeter (Tokyo, Japan) in a solution (0.01 M sodium phosphate, pH 7.4) at 25°C using a quartz cell of 1 mm path length. Wavelengths from 200 to 250 nm were measured with 0.1-nm step resolution, 50 nm/min speed, 0.5-s response time, and 1-nm bandwidth. The CD spectra of the mutants (0.4 mg/ml) were collected, averaged over four scans, and expressed as molecular ellipticity in degree⅐cm 2 ⅐mol Ϫ1 (ϫ10 5 ). To avoid signal interferences from GSTs two times bigger than FKBP12s, the GST moieties of GST-FKBP12s were cleaved by thrombin digestions before CD measurements.
RESULTS

Depletion of
FKBP12s from SR Vesicles-To determine the critical amino acid residues of FKBP12 involved in the interaction with RyR1, FKBP12-depleted SR vesicles were prepared by incubating rabbit skeletal SR vesicles in the presence of 20 M rapamycin for 15 min at 37°C as described under "Experimental Procedures." The intact SR and the FKBP12-depleted SR vesicles (ϪFSR) were subjected to SDS-PAGE (Fig. 1, A and C) and immunoblot analysis (Fig. 1, B and D) . The distributions of the high (Fig. 1A) and low (Fig. 1C ) molecular weight proteins both in intact SR and FKBP12-depleted SR were similar, suggesting that the treatment with rapamycin did not affect the general profiles of SR proteins. On the other hand, immunoblots with the anti-RyR1 and anti-FKBP12 antibodies showed that FKBP12 was completely removed from the SR vesicles after treatment with rapamycin ( Fig. 1D) without significant changes in the amount of RyR1s (Fig. 1C) . This result is consistent with the previous report (30) .
cDNA Cloning of FKBP12.6 from Rabbit Heart and Mutations of FKBP12 and FKBP12.6 -For the present study, we cloned FKBP12.6 cDNA from rabbit heart as described under "Experimental Procedures," and DNA sequencing was completed (GenBank TM accession number AY159324). The rabbit FKBP12.6 has 97.2% sequence homology (315 of 324 bp) compared with the human sequence (GenBank TM accession number L37086). At the amino acid level, only 1 of 108 amino acids is different from human FKBP12.6 (99.1% homology). As is seen in the human amino acid sequences (37, 38) , the highly conserved tryptophan found in FKBP12 is substituted by phenylalanine in FKBP12.6, which may be important for maintaining core aromatic side chains for forming a binding pocket for rapamycin. Fig. 2 shows amino acid sequence alignments of rabbit FKBP12 and FKBP12.6. The two isoforms have 82.4% se -FIG. 2. Comparison of amino acid sequences between rabbit FKBP12 and FKBP12.6 . The amino acid sequences are shown in the single letter format for each amino acid, and the identical amino acids between the two isoforms are indicated by dots. The numbering of the amino acids starts from the methionine residues. The mutation sites for FKBP12 and FKBP12.6 are indicated by the asterisk and pound symbols, respectively. The arrows show the N-terminal deletion site for the deletion mutations.
quence homology (89 of 108 amino acids). Among the 19 different amino acids, 6 amino acids (marked as a single asterisk in Fig. 2 ) that are differentially charged between FKBP12 and FKBP12.6 were subjected to site-directed mutagenesis. For Q3E and M49R, the amino acids of FKBP12 were changed to the corresponding ones in FKBP12.6, yielding increased negativity (Ϫ1 for Q3E) or positivity (ϩ1 for M49R). For R18A, R57A, H94A, and K105A, the positivity was decreased by alanine substitutions. For purification and in vitro binding assay, GST was fused to the N termini of the wild type and mutated FKBP12s by subcloning into the pGEX-4T vector as described under "Experimental Procedures."
In Vitro Binding Assay of GST-fused Wild Type FKBP12, Wild Type FKBP12.6, and Six Mutated FKBP12s (Q3E, R18A, M49R, R57A, H94A, and K105A)-The supernatants of the bacterial cell lysates expressing GST, GST-wtFKBPs (GST-fused wild type FKBP12 and FKBP12.6), GST-mFKBPs (GST-fused mutated FKBPs), and GST, GST-wtFKBPs, and GST-mFKBPs purified by glutathione-Sepharose 4B affinity beads and separated in 12% SDS-PAGE are shown in Fig. 3, A and B, respectively. The GST-FKBP12.6 showed relatively low expression levels (Fig. 3A) so that eight separate bead batches were combined together to bring the amount up to the other proteins. For in vitro binding between GST-FKBPs and RyR1, 100 g of immobilized GST-FKBPs on glutathione-Sepharose 4B affinity beads were incubated with 150 g of the Sol-FSR for 4 h at 4°C (Fig. 3C) . The results showed that both GST-FKBP12 and GST-FKBP12.6 bound to RyR1, consistent with the previous findings (17, 20) . However, Q3E, a simple reverse mutant from the amino acid in FKBP12 to FKBP12.6 and R18A, an alanine-substituted mutant, lost its binding ability to RyR1. The other reverse mutant, M49R, and alaninesubstituted mutants, R57A, H94A, and K105A, retained their binding ability to RyR1, suggesting that the interaction between FKBP12 and RyR1 is not simply because of chargecharge interaction.
In Vitro Binding Assay of Three Additional GST-mFKBP12s (E31Q, D32N, and W59F)-Three additional mutations of FKBP12 mimicking FKBP12.6 in the 31st, 32nd, and 59th positions (double asterisks in Fig. 2) were prepared, in light of the previous finding that these three residues in FKBP12.6 were important for binding to RyR2 (33) . The three reverse mutants (E31Q, D32N, and W59F), purified as described above (Fig. 4A) , were subjected to in vitro binding assay (Fig. 4B) . All of the three mutants bound RyR1, consistent with the previous report (33) , suggesting that those three residues in FKBP12 are not crucial for the interaction between FKBP12 and RyR1.
In Vitro Binding Assay of Two GST-mFKBP12.6s (E3Q and K18A)-In order to examine whether the N-terminal residues of FKBP12.6 are also important for the interaction between FKBP12.6 and RyR1, we prepared two FKBP12.6 mutants, E3Q and K18A, mimicking our FKBP12 mutants, Q3E and R18A, that did not bind RyR1, and the mutants were subjected to in vitro binding (Fig. 4, C and D) . Unlike the corresponding mutants of FKBP12, E3Q and K18A retained their binding ability to RyR1, suggesting that the molecular mechanism of the interaction between FKBP12.6 and RyR1 is different from that between FKBP12 and RyR1.
Measurements of CD Spectra for the Various mFKBP12s-To rule out the possibility that incorrectly folded mFKBP12s could affect their binding ability to RyR1, measurements of CD spectra for the mFKBP12s were conducted after removing the GST moieties (Fig. 5) . All the mutants including Q3E and R18A, except for the N-terminal 18 residue-deleted FKBP12 (Del-FKBP12), showed similar molar ellipticity to wtFKBP12, suggesting that there are no drastic changes in protein folding caused by the point mutations. Representative traces are shown in Fig. 5B .
Co-immunoprecipitation of Various GST-mFKBP12s with RyR1-To understand detailed interaction mechanisms between FKBP12 and RyR1, various amino acids having different size, charge, and hydrophobicity were introduced to the various positions of FKBP12. Fig. 6A shows 24 additionally and successfully purified GST-mFKBPs and GST-wtFKBP12. The supernatants (30 g) of bacterial cell lysates having all 33 GSTmFKBP12s were incubated with 80 g of the Sol-FSR. Furthermore, the samples were subjected to co-immunoprecipi- FIG. 3 . Purification of GST-wtFKBPs and GST-mFKBP12s using glutathione-Sepharose 4B affinity beads and in vitro binding assay with solubilized FKBP12-depleted SR vesicles. A, the supernatants of E. coli (BL21) lysates containing GST, GST-wtFKBPs, and GST-mFKBP12s were separated in a 12% SDS-PAGE, and the separated proteins were stained with Coomassie Blue. GST 0 was a negative control, pGEX-4T vector alone without any insert and with isopropyl-␤-D-thiogalactopyranoside induction. B, GST, GST-wtFKBPs, and GST-mFKBP12s were purified using glutathione-Sepharose 4B affinity beads and separated in a 12% SDS-PAGE. C, in vitro binding assays. After incubation of the purified GST-wtFKBPs and GSTmFKBP12s affinity beads with the solubilized ϪFSR (Sol-FSR, 150 g), and following elution of the bound proteins by SDS sample buffer, the proteins were subjected to a 6 or 12% SDS-PAGE for immunoblot with the anti-RyR1 or anti-FKBP12 antibody, respectively. The affinity beads without sample (Bead), Sol-FSR without affinity beads (Input), and GST-bound affinity beads with Sol-FSR (GST) as negative controls were also subjected to the in vitro binding assay. For comparison, immunoblots with SR, ϪFSR, and Sol-FSR were conducted in parallel.
tations as described under "Experimental Procedures." Fig. 6B shows a representative result of the co-immunoprecipitation experiments. Fig. 6C shows normalized relative intensities of each GST-mFKBP12 obtained from three independent experiments. Q3A, Q3E, Q3N, R18A, and M49A showed more than 50% reduction in intensity compared with GST-wtFKBP12. In the case of mutations in the 3rd position, all mutants having smaller side chains (Q3A and Q3N), differently charged side chains (Q3R and Q3E), or various hydrophobic side chains (Q3L and Q3W) showed drastically reduced binding ability, suggesting that the glutamine in the 3rd position is an irreplaceable residue for the binding of FKBP12 to RyR1. Although one could hypothesize that the large GST moiety affects the binding ability of the smaller FKBP12 near the site of the protein fusion, our co-immunoprecipitation studies with GSTfree FKBP12 and Q3A showed an identical reduction in Q3A binding (0.46 Ϯ 0.08 normalized intensity compared with GSTfree wtFKBP12), as seen using GST-fused wtFKBP12 and Q3A (Fig. 6, B and C, GST-fused Q3A had 0.43 Ϯ 0.27 normalized intensity compared with GST-fused wtFKBP12). Therefore, it is unlikely that the GST portion of the fusion proteins had significant effects on the binding of FKBP12 to RyR1.
On the other hand, in the cases of the 18th and 49th positions, only alanine substitution affected their binding ability to RyR1, suggesting that the methylene group (which is missing in R18A and M49A but not in other mutants of Arg-18 and Met-49) from the arginine and methionine residues in the 18th and 49th positions also plays an important role in the binding FIG. 4 . In vitro binding assay of additional three GST-mFKBP12s (E31Q, D32N, and W59F) and two GST-mFKBP12.6s (E3Q and K18A). A, three GST-mFKBP12s (E31Q, D32N, and W59F indicated by double asterisks in Fig. 2 ) were purified using glutathione-Sepharose 4B affinity beads and separated in 15% SDS-PAGE. B, in vitro binding assay of purified E31Q, D32N, and W59F affinity beads was performed with the Sol-FSR (150 g). C, two GST-mFKBP12.6 (E3Q and K18A indicated by pound signs in Fig. 2 ) were purified using glutathione-Sepharose 4B affinity beads and separated in 15% SDS-PAGE. D, in vitro binding assay of purified E3Q and K18A affinity beads was performed with the Sol-FSR (150 g). The experiments were conducted as described in the legend of Fig. 3 . As negative controls, Bead, Input, and GST were also used for the in vitro binding assay.
FIG. 5.
Measurements of CD spectra for wtFKBP12, mFKBPs, and Del-FKBP12. GST-wtFKBP12, various GSTmFKBP12s, and the N-terminal 18 residue-deleted GST-FKBP12 (GST-Del-FKBP12) were purified using glutathione-Sepharose 4B affinity beads. For measurements of CD spectra without any signal interference, GST moiety was selectively removed from the fusion proteins by thrombin digestions. CD spectra of wt-FKBP12, representative of eight mutants for Gln-3 and Arg-18, and Del-FKBP12 are shown. The spectra are expressed as molecular ellipticity in degree⅐cm 2 of FKBP12 to RyR1. Most interesting, the arginine and methionine residues are located close to each other in the threedimensional structure of FKBP12 (Fig. 7) .
DISCUSSION
In the present study, we conducted site-directed mutagenesis and N-terminal deletions of FKBP12 and FKBP12.6. In vitro binding assays and co-immunoprecipitations of GST-fused mutated FKBPs with FKBP12-depleted SR vesicles from rabbit skeletal muscle suggest that the N-terminal region of FKBP12 (Gln-3 and Arg-18) and Met-49 is responsible for the distinctive binding of FKBP12 to RyR1. These three residues are different from the three residues reported previously as crucial for the binding of FKBP12.6 to RyR2 (Gln-31, Asn-32, and Phe-59) (33) . This remarkable difference is unexpected, considering the fact that the similarity in the sequence and the structure is quite high between FKBP12 and FKBP12.6.
FKBP12 has a fold composed of five ␤-strands wrapping around a short ␣-helix with an overall conical shape (Fig. 7 , Protein Data Bank code 1FKB). The active site for PPIase action is at the cavity defined by a ␤-strand, the ␣-helix and three loops with a set of hydrogen bonds and an unusual carbonyl binding pocket (37) . Besides the enzymatic function, the cavity serves as the binding site for rapamycin/FK506 as well as for the place where various protein-protein interactions occur, which are clearly seen in the complex structures of FKBP12 with FKBP-rapamycin associated protein, calcineurin A and B, or type I transforming growth factor-␤ receptor (39 -42) . In FKBP12.6, residue Phe-59, which forms the seat of the hydrophobic ligand-binding site in the cavity, was found to be crucial for binding of FKBP12.6 to RyR2 (33) . Residue Trp-59 of FKBP12 was suggested as the determinant for the selective binding of FKBP12 to RyR1 (43); however, our result shows FIG. 6 . Purification and co-immunoprecipitation of various GSTmFKBP12 and RyR1. A, GST-wt-FKBP12 and various GST-mFKBP12s were purified using glutathione-Sepharose 4B affinity beads and separated in 15% SDS-PAGE. B, for the immunoprecipitation (IP), the anti-RyR1 antibody and protein G-Sepharose affinity beads were used after incubating each GSTmFKBP12 with the Sol-FSR (80 g), and the immunoprecipitants were subjected to immunoblot (IB) with the anti-RyR1 (IB, RyR1) and anti-FKBP12 antibodies (IB, FKBP12) as described under "Experimental Procedures." The Sol-FSR without GST-fused protein (ϪFSR) and GST with Sol-FSR (GST alone) as negative controls were also subjected to immunoprecipitation. C, the results of co-immunoprecipitations are summarized as a bar graph. The band intensities of GSTmFKBP12s were normalized by that of GST-wtFKBP12. For comparison, the full intensity and half-intensity levels of GSTwtFKBP12 were indicated by solid and dashed lines, respectively. The mutants showing more than 50% reduction in the normalized intensity (Q3A, Q3E, Q3N, K18A, and M49A) are indicated by white asterisks. There are no drastic differences in the amounts of RyR1 (as shown by immunoblot (IB), RyR1). The data are the mean Ϯ S.E. of three independent experiments. correspond to those of three residues Gln-31, Asn-32, and Phe-59 that were found to be important for the interaction between FKBP12.6 and RyR2. The figure shows the noticeable divergence in the locations of the RyR-interacting residues between FKBP12 and FKBP12.6. These figures were generated using the program PyMOL (52) .
that this conserved interaction model for the ligand-binding site does not hold.
It is noteworthy that the residues of FKBP12 necessary for binding to RyR1 are more distant from the active site than those of FKBP12.6 for binding to RyR2. In FKBP12.6, the residues Gln-31, Asn-31, and Phe-59 important for binding to RyR2 are located closely around the active site cleft (33) . On the contrary, in the three-dimensional structure of FKBP12, the residue Gln-3 is positioned relatively close to residues 31 and 32, but the residues Arg-18 and Met-49 are located at the opposite side of the residue Gln-3 about 20 Å away (Fig. 7) . When all the N-terminal 18 residues covering Gln-3 and Arg-18 were removed, FKBP12 lost the binding ability to RyR1 (data not shown). However, according to the CD measurements, the deletion of the N-terminal 18 residues hampered the proper folding and functionality of the FKBP12, suggesting that the N-terminal 18 residues also play an important role in its proper folding (Fig. 5) , although it was found that the N-terminal ␤1-strand covered by the N-terminal 18 residues is formed to a lesser degree in the transition state than the central three ␤-strands 2, 4, and 5 (44) . On the other hand, the GST-Del-FKBP12.6 lacking the N-terminal 18 residues still retained the ability to bind RyR1 (data not shown). Thus the interaction via the N terminus with RyR1 is unique to FKBP12.
In order to examine the possible interaction mechanisms between the N terminus of FKBP12 and RyR1, we conducted co-immunoprecipitations of various GST-mFKBP12s with RyR1, and we found that the glutamine residue in 3rd position was irreplaceable. Considering that the carbonyl oxygen and amino protons in the glutamine could serve as hydrogen bond acceptor and donor, respectively, it is possible that the precise geometry of hydrogen bond acceptor/donor in 3rd position is crucial for the interaction between FKBP12 and RyR1.
On the other hand, residues Arg-18 and Met-49 showed the reduced binding ability only with alanine substitutions. As these two residues are located close to each other in the threedimensional structure of FKBP12 (Fig. 7) and their methylene groups participate in a hydrophobic surface patch with hydrocarbons from Lys-17, Gly-19, and Gln-20, this suggests that a hydrophobic interaction of the methylene groups in 18th and 49th positions also plays an important role in the binding of FKBP12 to RyR1. Taken together, integration of the possible hydrogen bonds by Gln-3 and the hydrophobic interactions by Arg-18 and Met-49 appears to be the mechanism for FKBP12-RyR1 binding (Fig. 7) .
Although Gln-3, Arg-18, and Met-49 governed the binding ability of FKBP12 to RyR1, our study does not exclude the marginal contribution of the active site of FKBP12 as a PPIase for binding of FKBP12 to RyR1. The valine-proline 2461-2462 residues of RyR1 are thought to be critical for the high affinity interaction with FKBP12 (45). Gaburjakova et al. (45) suggested that the conserved dipeptide motif of the hydrophobic peptide (valine-, leucine-, or isoleucine-proline) in three RyR isoforms and inositol 1,4,5-trisphosphate receptor may occupy the active site of the FKBP12 as a PPIase by mimicking its substrate. However, the mutation of tryptophan into phenylalanine (W59F) only weakly reduced the binding of FKBP12 to RyR1 (Fig. 6C) . Thus the interactions between the active site of FKBP12 and RyR1 must be less selective than the interaction with the inositol 1,4,5-trisphosphate receptor and are not strong enough to form a stable complex.
The 136-amino acid fragment (residues 2361-2496) of the human RyR2 containing the corresponding isoleucine-proline motif (residues 2427-2428 of RyR2) is defined as the FKBP12.6-binding site in RyR2 (31); however, Zissimopoulos and Lai (46) found that a large C-terminal fragment of human RyR2 encompassing all 10 transmembrane helices interacts with FKBP12.6 rather than the 10 overlapping fragments covering the isoleucine-proline motif. In addition, Masumiya et al. (47) suggested that the region between residues 1636 and 1937 of RyR2, encompassing the divergent region 3 (DR3) among the three RyR isoforms, is required for FKBP12.6 interaction. These contradictory observations with RyR2 raise the possibility that, unlike RyR1, the FKBP-binding region in the RyR2 consists of not only a conserved dipeptide motif but also the remote region of the sequence (47) (48) (49) (50) (51) , emphasizing again that the interacting mechanism of FKBP12 and FKBP12.6 with RyRs could be different. The detailed interacting mechanism of interaction between FKBP12 and RyR1 must await solutions for the crystal structures of the complex in the future.
